Фибрилляция предсердий с дебютом в детском возрасте, вероятно ассоциированная с вариантом D1907H в гене SCN10A

   Фибрилляция предсердий является самой частой устойчивой аритмией у взрослых, однако у детей она встречается достаточно редко. У пациентов без структурной патологии сердца или экстракардиальных причин можно предположить генетическую основу заболевания. В статье описан клинический случай фибрилляции предсердий у ребенка, вероятно ассоциированный с вариантом D1907H в гене SCN10A. Несмотря на ограниченную информацию об ассоциации канала Nav 1.8, кодируемого SCN10A, с предсердными нарушениями ритма, представленный случай может служить дополнительной иллюстрацией возможной роли этого гена в развитии аритмии у детей.

1. Hindricks G., Potpara T, Dagres N, et al. ESC Scientific Document Group, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. DOI: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021; 42 (5): 507. Erratum in: Eur Heart J. 2021; 42 (5): 546–547. Erratum in: Eur Heart J. 2021;(40):4194.

2. Benjamin E. J., Muntner P., Alonso A., et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American

3. Heart Association. Circulation. 2019; 139 (10): e56–e528. DOI: 10.1161/CIR.0000000000000659. Erratum in: Circulation. 2020; 141 (2): e33.

4. Gourraud J. B., Khairy P., Abadir S., et al. Atrial fibrillation in young patients. Expert Rev Cardiovasc Ther. 2018; 16 (7): 489–500. DOI: 10.1080/14779072.2018.1490644.

5. Brugada J., Blom N., Sarquella-Brugada G., et al. European Heart Rhythm Association; Association for European Paediatric and Congenital Cardiology. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013; 15 (9): 1337–82. DOI: 10.1093/europace/eut082.

6. Mills L. C., Gow R. M., Myers K., et al. Lone atrial fibrillation in the pediatric population. Canadian Journal of Cardiology 2013; 29: 1227–33. DOI: 10.1016/j.cjca.2013.06.014.

7. Kammeraad J. A., van Deurzen C. H., Sreeram N., et al. Predictors of sudden cardiac death after Mustard or Senning repair for transposition of the great arteries. J Am Coll Cardiol. 2004; 44 (5): 1095–102. DOI: 10.1016/j.jacc.2004.05.073.

8. Mandalenakis Z., Rosengren A., Lappas G., et al. Atrial Fibrillation Burden in Young Patients With Congenital Heart Disease. Circulation. 2018; 137 (9): 928–937. DOI: 10.1161/CIRCULATIONAHA.117.029590.

9. Martin T. C., Hagenbuch S. C. Atrial Fibrillation in Children. In: Choi, J, ed. Atrial Fibrillation — Basic Research and Clinical Applications [Internet]. London: Intech Open, 2012: 349–372. Available from: https://www.intechopen.com/chapters/25810. DOI: 10.5772/26547.

10. Kovalchuk T., Yakovleva E., Fetisova S., et al. Case Reports: Emery-Dreifuss Muscular Dystrophy Presenting as a Heart Rhythm Disorders in Children. Front Cardiovasc Med. 2021; 8: 668231. DOI: 10.3389/fcvm.2021.668231.

11. Kornej J., Börschel C. S., Benjamin E. J., et al. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020; 127 (1): 4–20. DOI: 10.1161/CIRCRESAHA.120.316340.

12. Darbar D., Roden D. M. Genetic mechanisms of atrial fibrillation: impact on response to treatment. Nat Rev Cardiol. 2013; 10 (6): 317–329. DOI:10.1038/nrcardio.2013.53.

13. Staerk L., Sherer J. A., Ko D., et al. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res. 2017; 120 (9): 1501–1517. DOI:10.1161/CIRCRESAHA.117.309732.

14. Lozano-Velasco E., Franco D., Aranega A., et al. Genetics and Epigenetics of Atrial Fibrillation. Int J Mol Sci. 2020; 21 (16): 5717. DOI:10.3390/ijms21165717.

15. Faber C. G., Lauria G., Merkies I. S., et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci USA. 2012; 109 (47): 19444–9. DOI: 10.1073/pnas.1216080109.

16. Macri V., Brody J. A., Arking D. E., et al. Common Coding Variants in SCN10A Are Associated With the Nav1.8 Late Current and Cardiac Conduction. Circ Genom Precis Med. 2018; 11 (5): e001663. DOI: 10.1161/CIRCGEN.116.001663.

17. Christophersen I. E., Ellinor P. T. Genetics of atrial fibrillation: from families to genomes. J Hum Genet. 2016; 61 (1): 61–70. DOI: 10.1038/jhg.2015.44.

18. Savio-Galimberti E., Weeke P., Muhammad R., et al. SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation. Cardiovasc Res. 2014; 104 (2): 355–363. DOI:10.1093/cvr/cvu170.

19. Jabbari J., Olesen M. S., Yuan L., et al. Common and rare variants in SCN10A modulate the risk of atrial fibrillation. Circ Cardiovasc Genet. 2015; 8 (1): 64–73. DOI:

20. 1161/HCG.0000000000000022. Erratum in: Circ Cardiovasc Genet. 2016; 9 (1): 100.

21. Hu D., Barajas-Martínez H., Pfeiffer R., et al. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. J Am Coll Cardiol. 2014; 64 (1): 66–79. DOI: 10.1016/j.jacc.2014.04.032.

22. Monasky M. M., Micaglio E., Vicedomini G., et al. Comparable clinical characteristics in Brugada syndrome patients harboring SCN5A or novel SCN10A variants. Europace. 2019; 21 (10): 1550–1558. DOI: 10.1093/europace/euz186.